LAPTM5 and renal cell carcinoma: LAPTM5 displayed remarkably higher expression levels in lung metastases than in bone (P < 0.001) and brain metastases (P = 0.039), and primary RCC tissues (P < 0.0001) (Fig. 7a, b).